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Background: Several studies demonstrated that epidermal growth factor receptor (EGFR) gene copy number
(GCN) correlates to the response to tyrosine kinase inhibitors in non small cell lung cancer (NSCLC) and to anti-
EGFR monoclonal antibodies (MoAbs) in metastatic colorectal cancer (CRC). In the presence of lung nodules,
cytology is often the only possible diagnostic approach. Chromogenic in situ hybridization (CISH) is an alternative
technique to fluorescence in situ hybridization (FISH), but its feasibility in detecting EGFR GCN in cell blocks from
fine-needle aspiration cytology (FNAC) of lung nodules has not yet been established.
Methods: We evaluated the feasibility of CISH on 33 FNAC from 20 primary NSCLC (5 squamous carcinomas,
8 large cell carcinomas and 7 adenocarcinomas) and 13 lung metastases from CRC.
Results: Of the 33 FNAC analyzed by CISH, 27 (82%) presented a balanced increase in EGFR gene and
chromosome 7 number: 10 cases (30%) showed a low polysomy, 15 (45%) a high polysomy and 2 (6%) NSCLC
were amplified. No significant differences between NSCLC and CRC lung metastases were found in relation to
disomic or polysomic status. In addition, no correlation between EGFR GCN and EGFR immunohistochemical
overexpression was found. Furthermore, we compared CISH results with those obtained by FISH on the same
samples and we found 97% overall agreement between the two assays (k = 0.78, p < 0.0001). Two cases were
amplified with both assays, whereas 1 case of NSCLC was amplified by FISH only. CISH sensitivity was 67%, the
specificity and positive predictive value (PPV) was 100%, and the negative predictive value (NPV) was 97%.
Conclusions: Our study shows that CISH is a valid method to detect EGFR GCN in cell blocks from FNAC of
primary NSCLC or metastatic CRC to the lung.
Introduction
Epidermal growth factor receptor (EGFR) is a member
of the erbB family of tyrosine kinases (TK) receptor pro-
teins, that play an important role in tumor progression
[1]. In fact, the binding EGFR/ligand leads to activation
of the TK, thus inducing cell growth, inhibition of
apoptosis, angiogenesis, invasion and metastasis [2].
EGFR overexpression in non small cell lung cancer
(NSCLC) and colorectal cancer (CRC) is a frequent
event related to a poor outcome [3]. In the last few
years, many clinical trials h a v ep r o v e nt h ee f f i c a c yo f
EGFR-targeted therapies in the management of several
cancers, including breast, colon, pancreas, head and
neck, renal, and lung carcinomas. Multiple therapeutic
strategies have been develop e dt ot a r g e tE G F R ,i n c l u d -
ing monoclonal antibodies (MoAbs), tyrosine kinase
inhibitors (TKI), ligand-toxin conjugates, and antisense
oligonucleotides. Cetuximab and panitumumab are two
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of EGFR with high specificity and higher affinity for
EGFR than the natural ligands TGF-a and EGF, and are
now considered as one standard option for patients with
advanced CRC in the first or second line of treatment
[4,5]. Indeed, the anti-EGFR erlotinib and gefitinib have
undergone extensive clinical testing demonstrating clini-
cal activity in NSCLC [6].
In this context, there is a need for methods enabling
response prediction in order to select those patients
most likely to benefit from treatment. Therefore, the
diagnostic approach of pathologists is changing, leading
to an integrated morphological and molecular diagnosis.
EGFR overexpression does not seem a good predictor of
response to treatment both in NSCLC and CRC [7,8],
even though some controversial results are reported [9].
According to poor clinical information obtained from the
immunohistochemistry (IHC), the interest in EGFR gene
status increased after Moroni et al [10] proposed that in
CRC the response to anti EGFR treatment with cetuximab
is related to EGFR gene copy number (GCN) and Lynch
et al [11] showed that, in advanced NSCLC, in-frame dele-
tion or missense mutations in the EGFR TK domain can
predict the response to therapy with gefinitib.
In addition, several authors [12,13] reported that, in
metastatic CRC (mCRC), an increased EGFR GCN or
mutations of genes (i.e. k-ras) responsible for down-
stream signalling are important determinants of
response or resistance to anti-EGFR antibodies, such as
cetuximab and panitumumab. Specifically, cetuximab
has proven efficacy in the treatment of mCRC, but also
in NSCLC with squamous cell histology [14].
Although fluorescence in situ hybridization (FISH) is
the “gold standard” method to detect EGFR gene amplifi-
cation, this technique presents some disadvantages since
the fluorescent signal is not stable and morphological
features are difficult to visualize. In contrast, chromo-
genic in situ hybridization (CISH) utilizes a peroxidase
reaction to detect the locus of interest and can be inter-
preted by standard light microscopy in the context of
morphology [15].
In the majority of lung neoplastic nodules, cytology is
often the only possible diagnostic approach. Neverthe-
less, the cytological diagnosis of pulmonary nodules
sampled by fine-needle aspiration cytology (FNAC) pre-
sented three main problems for the pathologist: a) the
small amount of cellular specimens, b) the correct char-
acterization of tumor histotype, and c) the report of bio-
logical information predictive of targeted therapy
response. Conventional cytology can often provide insuf-
ficient material to answer these problems, while the
availability of cell blocks allowed to perform multiple
analyses as IHC, CISH/FISH and eventually gene muta-
tions [16].
In a retrospective series of 33 pulmonary tumors, we
investigated the feasibility and reliability of CISH per-
formed in cell blocks obtained from FNAC, to detect
EGFR gene copy number both in primary NSCLC and
mCRC lung nodules. In addition, we compared CISH to
FISH and IHC results.
Materials and methods
Patients and samples
Cell blocks from paraffin embedded FNAC of 33 lung
neoplastic nodules were retrospectively selected from
the Pathology Department Archives of the National
Cancer Institute of Bari, Italy.
Twenty primary lung carcinomas, 18 from male and
2 from female patients, and 13 metastatic lung nodules
from CRC (10 males and 3 females) were included in
this study. Five of the 20 NSCLC were squamous cell
carcinomas (SCC), 8 large cell carcinomas (LCC), and
7 adenocarcinomas (ADC). The median age of patients
was 67 (range: 31-84 years).
FNAC samples were obtained with a CIBA 22-gauge
needle (length 15 cm), and the aspiration procedure was
performed under computed tomography (CT) guidance.
All patients provided their written consent for use of
the samples for research purposes.
Cell Block Procedure
Cell blocks were prepared spinning the FNAC cellular
specimens, fixed in 10% buffered formalin, at 1000 revo-
lutions per minute for 10 minutes. After centrifugation,
the sediment was re-suspended in 95° ethyl alcohol for
10 minutes and submitted to a second centrifugation.
Then, the packed sediment was removed with a spatula
and wrapped in lens paper. The wrapped sediment was
embedded in paraffin according to conventional histolo-
gical techniques after a short processing cycle with
xylene.
Five consecutive 3-4 μm thick sections were cut from
cell block of all 33 cases and processed by IHC to evalu-
ate EGFR expression and by CISH and FISH to analyze
gene amplification. The cytological slides were reviewed
by a pathologist (GS), who verified the diagnosis and the
percentage of neoplastic cells.
Immunohistochemistry
The immunohistochemical assay for EGFR expression
was performed on tissue sections from cell blocks using
the EGFR PharmDx kit (Dako, Milan, Italy).
The deparaffinized and rehydrated sections were pre-
treated in an enzyme solution (Proteinase-k) at room
temperature (RT) for 5 minutes. After the block of
endogenous peroxidase activity, the sections were incu-
bated with EGFR MoAb (IgG1, clone 2-18C9, Dako) for
30 minutes, employing 3’3-diaminobenzidine (DAB) as a
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stained with Mayer’s hematoxylin and mounted in aqu-
eous mounting medium (Glicergel, Dako).
Dako control slides were used as positive controls and
the negative control was performed by omitting the
application of the primary antibody.
IHC scoring was based on the membrane immunor-
eactivity, according to the American Joint Committee
[17]: 0, no reactivity, 1+, weak reactivity, 2+, moderate
reactivity, 3+, strong reactivity.
Chromogenic in situ hybridization
Formalin fixed paraffin embedded (FFPE) sections were
deparaffinized, dehydrated, air dried, and heated in boil-
ing tissue heat pre-treatment buffer for 15 minutes
using a SPoT-Light® FFPE reagent kit (Zymed, Histoline,
Milan, Italy). Enzymatic digestion was performed using
SPoT-Light® FFPE digestion enzyme (Zymed) for 2-3
minutes at RT. After dehydration, histological slides
were air dried and the ready-to-use double-stranded
DNA digoxygenin-labelled EGFR probe (Zymed) or the
biotin labelled chromosome 7 centromeric probe
(Zymed) were applied. Denaturation was performed by
incubating the slides, covered with a CISH cover-slip,
on a 96°C heating block for 5 minutes, and hybridization
was performed by placing the slides in a humidity
chamber at 37°C overnight. After removing the cover-
slips, a stringent wash was performed in 0.5× saline-
sodium citrate buffer at 80°C for 5 minutes. The
endogenous peroxidase activity and unspecific staining
were blocked by applying 3% hydrogen peroxide and the
CAS-Block™, respectively. A mouse antidigoxygenin anti-
body was added to the slides hybridized with EGFR
probe for 45 minutes at RT followed by incubation with
a polymerized peroxidase-goat anti-mouse antibody
(Dako) for 45 minutes at RT. On the FFPE tissue slides,
the colorimetric signal of chromosome 7 centromeric
probe was improved by incubating the slides with a
mouse antibiotin antibody (Dako) for 45 minutes at
37°C. A DAB chromogen substrate system was used to
generate a sensitive signal that could be viewed with a
Nikon ECLIPSE 55i transmission light-brightfield micro-
scope (Nikon, Amstelveen, The Netherlands) after
Mayer’s haematoxylin counterstaining.
Fluorescence in situ hybridization
FISH was performed using the LSI EGFR (SpectrumOr-
ange™), a locus-specific probe for the EGFR human gene
locus (7q12) and the chromosome enumeration probe
(CEP 7, SpectrumGreen™) for alpha-satellite DNA
located at the centromere (7q11.1-q11.1) (Vysis, Inc.,
Downers Grove, IL). The assay was carried out accord-
ing to the manufacturer’s instructions. Shortly after
deparaffinization, the FFPE specimens were incubated in
the pre-treatment solution (82°C, 30 minutes) and then
digested with protease (37°C, 15 minutes). After wash-
ing, the slides were counterstained with 4’,6-diamidino-2
phenylindole (DAPI) and analyzed using a fluorescent
microscope. An average of 30 nuclei was counted for
each case. The EGFR gene copy number, chromosome 7
copy number, and the average EGFR gene to chromo-
some 7 signal ratio were reported as FISH genetic
variables.
CISH and FISH analysis
The CISH and FISH results were assessed using the
categories proposed by Daniele et al. [18]. Four majors
patterns were identified: balanced disomy (1.6-2.0 gene
and chromosome 7 in all cells), balanced trisomy
(2.2-3.0 gene and chromosome 7), balanced polysomy
(3.1-4.4 gene and chromosome 7), low amplification
(gene-to-chromosome 7 ratio 2.1-3.0), and high amplifi-
cation (gene-to-chromosome 7 ratio > 3.0). We consid-
ered the presence of at least a group of 10 neoplastic
cells showing gene gain as the positive cut off.
The CISH and FISH signals were read by 2 investiga-
tors (MM and ADB) independently from the results of
the other assays.
Statistical Analysis
Agreements between the test results (IHC, CISH and
FISH) were estimated using the Cohen’s k test and its
relative 95% confidence interval (95% CI). Specificity,
sensitivity, negative and positive predicted value (NPV
and PPV, respectively), concordance and the 95% CI of
the CISH assay were estimated considering the FISH
result as the gold standard. Significance was assessed at
5% level. The statistical software package used for this
analysis was SPSS for Windows (version 17.0; SPSS Inc.,
Chicago IL, USA).
Results
EGFR gene copy number according to tumor histotype
The CISH analysis was performed successfully on cell
blocks of 20 NSCLC and 13 pulmonary mCRC. Of the
33 FNAC samples analyzed, 27 (82%) presented an
increased EGFR GCN. In detail, as summarized in Table
1, 6 cases (18%) were disomic (1.6-2.0 balanced gene
and chromosome 7) (fig 1A, B), 10 (30%) presented low
polysomy (trisomy: 2.2-3.0 balanced gene and chromo-
some 7) and 15 (45%) high polysomy (3.1-4.4 balanced
gene and chromosome 7). The 2 amplified NCSLC
(gene-to-chromosome 7 ratio ≥ 2), were 1 ADC and 1
LCC (fig 1C, D). No significant differences between
NSCLC and pulmonary metastases from CRC, were
observed in relation to the disomic or polysomic status.
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CISH and FISH
Positive immunoreactivity for EGFR was observed in
72% of the 33 cases and was distributed as follows: 65%
NCSLC and 84% lung metastasis from CRC.
According to the IHC scoring system, 16 cases (8/20
NSCLC and 8/13 pulmonary mCRC) showed an intense
EGFR-immunoreactivity (score 3+) (fig 2), 5 moderate
reactivity (score 2+) and 3 weak reactivity (score 1+).
No immunoreactivity (score 0) was observed in 9 cases
(7 NSCLC and 2 mCRC). In particular, among the 27
polysomic cases detected by CISH (12 low polysomy, 15
high polysomy), 17 (63%) scored 2+/3+ (6 NSCLC and
11 pulmonary mCRC), and 10 (37%) scored 0/1+
(8 NSCLC and 2 pulmonary mCRC). The 2 NCSLC
amplified by CISH displayed a 3+ score. We did not
observe any statistically significant correlation between
IHC scores and CISH (p = .85).
Furthermore, a comparison between CISH and FISH
was performed. FISH evidenced 4 disomic (1.6-2.0
balanced gene and chromosome 7) (16%) and 26 polysomic
Table 1 Distribution of EGFR gene copy number
evaluated by CISH according to tumor histotype
Histotype N° of cases Disomy Trisomy Polysomy Amplified
ADC 7 1 2 3 1
LCC 8 2 1 4 1
SCC 5 1 3 1 0
mCRC 13 2 4 7 0
Total 33 6 10 15 2
ADC: adenocarcinoma; LCC: large cell carcinoma; SCC: squamous cell
carcinoma; mCRC: metastatic colo-rectal cancer; Disomy: 1.6-2.0 balanced
gene and chromosome 7; Trisomy: balanced 2.2-3.0 gene and chromosome 7;
Polysomy: 3.1-4.4 balanced gene and chromosome 7; Amplified: gene-to-
chromosome 7 ratio ≥ 2
Figure 1 EGFR CISH analysis on non small cell lung carcinoma. Two different patterns of gene and chromosome 7 copy number obtained
by CISH on cell blocks prepared from two different Lung Carcinoma FNAC: (A) EGFR not amplified and (B) paired chromosome 7 disomy; (C)
EGFR gene amplification with a clustered pattern and (D) trisomy of chromosome 7. Original magnification ×1000.
Figure 2 Immunocytochemical evaluation of EGFR on non small
cell lung carcinoma. Immunohistochemistry for EGFR in large cell
carcinoma (LCC) FNAC cell block evidencing a strong membrane
immunoreactivity (score 3+). Original magnification ×400.
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gene and chromosome 7) and 19 were highly polysomic
(3.1-4.4 balanced gene and chromosome 7) and 3 ampli-
fied (gene-to-chromosome 7 ratio ≥ 2). Sensitivity for
CISH was 60%, specificity was 89%, the positive predictive
value (PPV) was 50% and the negative predictive value
(NPV) was 93% (Table 2).
Table 3 reported the correlation between EGFR gene
and chromosome 7 balanced polysomy by CISH and
FISH. The overall concordance between FISH and CISH
results was 97%. We observed 30 out of 33 cases not
amplified (NA) and 2 NCSLC amplified (A) with both
assays. CISH presented a gene-to-chromosome 7 ratio
of 2.5 and 3 respectively and FISH a gene-to-chromo-
some 7 ratio of 2.8 and 3.3 respectively. Although there
was a very low number of amplified cases, the 2 NSCLC
FNAC with gene amplification by CISH were highly
polysomic and this polysomy was confirmed by FISH.
Only 1 NSCLC was NA by CISH (gene-to-chromo-
some 7 ratio 1.2) and amplified by FISH (gene-to-chro-
mosome ratio 2.5). The k coefficient for the inter-assay
agreement was 0.78 (95% CI: 45%-100% P < 0.0001).
Therefore, sensitivity for CISH was 67%, specificity was
100%, PPV was 100% and NPV was 97%.
Discussion
The present study aimed to evaluate the effectiveness of
CISH to detect EGFR GCN on FFPE sections from
FNAC cell blocks obtained from NSCLC and CRC pul-
monary metastases.
Our findings demonstrated that: a) lung FNAC nodules
provide useful material to detect the EGFR status by in
situ hybridization, b) the CISH technique is sensitive and
specific in determining EGFR GCN, c) CISH and FISH
correlate between them, while there is no association
between EGFR GCN and IHC overexpression.
Previous studies already demonstrated that CISH is a
useful technique for the detection of EGFR and HER2
gene amplification in breast [19] and lung cancer [18]
FNAC both in conventional and in monolayered smears
obtained by liquid based cytology.
H e r e i n ,w es h o w e dt h a tt h eCISH analysis performed
on cell blocks from lung FNAC is also a valuable
method for establishing the EGFR gene content in pul-
monary neoplastic nodulesa n d ,a sr e p o r t e db yo t h e r
authors [18,20], there is a close association with the
results provided by FISH.
To our knowledge, no previous studies have made a
direct comparison between the CISH and FISH analyses
in cytological specimens from lung tumors using cell
block preparation. This methodological approach could
be of clinical interest in the diagnosis of lung nodules
since it may reduce the undetermined diagnoses distin-
guishing tumor histotype known to better respond to
anti-EGFR targeted therapies [21,22].
Primary lung carcinomas as well as mCRC are often
unresectable [23] leading to the use of FNAC proce-
dures or bronchoscope tissue biopsy to obtain diagnostic
cellular material. However, conventional cytology has
not been widely used for biological analysis, primarily
due to heterogeneity within samples or to the limited
percentage of tumor cells usually present in the cytolo-
gical smears. The method we described may be particu-
larly useful in patients who are not candidates for
surgery and may be used also on other cytological speci-
mens as pleural effusions or bronchoalveolar lavages. In
o u rs e r i e so f2 0p r i m a r yN S C L Ca n d1 3m C R C ,C I S H
evidenced EGFR gene amplification only in NSCLC (2/
20, 10%) and an elevated incidence of high polysomy
(40% NSCLC and 53% mCRC). The low number of
amplified cases we found is in line with data reported in
the recent literature showing that EGFR gene is rarely
amplified in human cancers. In contrast, an increased
EGFR GCN with balanced polysomy is more frequent
occurring in approximately 25 to 40% of patients with
NSCLC or CRC [24].
Table 2 Comparison between immunohistochemistry,
CISH and FISH in 33 cell blocks from lung FNAC
IHC score N° of cases CISH FISH
DTPA D TPA
09 1 5 3 0 2 2 5 0
1+ 3 1 0 2 0 0 0 3 0
2+ 5 1 0 4 0 0 0 5 0
3+ 16 2 7 6 2 2 5 6 3
Total 33 5 12 14 2 4 7 19 3
IHC: immunohistochemistry; CISH: chromogenic in situ hybridization; FISH:
fluorescence in situ hybridization;
D: disomy, 1.6-2.0 balanced gene and chromosome 7; T: trisomy, 2.2-3.0
balanced gene and chromosome 7; P: polysomy, 3.1-4.4 balanced gene and
chromosome 7; A: amplified, gene-to-chromosome 7 ratio ≥2
Sensitivity 60%; Specificity 89%; Positive predictive value 50%; Negative
predictive value 93%
Table 3 Comparison between CISH and FISH in 33 cell
blocks from lung FNAC
CISH FISH
EGFR status Chromosome 7 EGFR status Chromosome 7
Disomy Polysomy Disomy Polysomy
31 NA 6 (19%) 25 (81%) 30 NA 4 (13%) 26 (87%)
Disomy Polysomy Disomy Polysomy
2 A 0 2 (100%) 3 A 1 (33%) 2 (67%)
Total 33 6 27 33 5 28
CISH: chromogenic in situ hybridization; FISH: fluorescence in situ
hybridization; NA: not amplified, gene-to-chromosome 7 ratio < 2; A:
amplified, gene-to-chromosome 7 ratio ≥2; Disomy: 1.6-2.0 balanced gene and
chromosome 7; Polysomy: 3.1-4.4 balanced gene and chromosome 7
Concordance 97%; k = 0.78; p < 0.0001; Sensitivity 67%; Specificity 100%;
Positive predictive value 100%; Negative predictive value 97%
Simone et al. Journal of Experimental & Clinical Cancer Research 2010, 29:125
http://www.jeccr.com/content/29/1/125
Page 5 of 7Discrepancy in EGFR gene amplification between
CISH and FISH was found in one NSCLC case. This
discordance may be likely due to the lower polysomy
observed by FISH. Therefore, an agreement of 97%
(k = 0.78; p < 0.0001) between CISH and FISH was
detected in the total series of 33 patients without any
significant differences between primary and metastatic
lung nodules.
We verified that, even though the majority of samples
were assessable by both the techniques, some samples
were more difficult to evaluate by FISH because of high
autofluorescent background due to the presence of
hemosiderin or necrosis. The use of CISH allowed a
simultaneous evaluation of GCN, tumor cells and
detailed surrounding tissue morphology on the same
slide.
Many authors demonstrated that the increase in abso-
lute EGFR GCN detected by FISH, both in NSCLC and
in mCRC [9,13], is associated with an improved
response to TKI as gefitinib or to cetuximab or panitu-
mumab respectively. Only a few studies did not confirm
this predictive value [25,26]. More recently, it has been
reported that in NSCLC, EGFR gene mutation is more
significantly related to the response of targeted therapy
to TKI [24]. In addition, some authors [18,27,28]
showed, both in bioptic and cytological specimens, that
a balanced increase of EGFR gene and chromosome 7
copy number is related with specific EGFR mutations.
Therefore, NSCLC presenting a EGFR balanced polys-
omy had a high probability of response to gefinitib. Sev-
eral studies have compared whether EGFR abnormalities
in NSCLC, detectable by IHC, in situ hybridization or
PCR, correlate with each other or represent independent
variables [9,18]. Recently, a meta-analysis of nearly 5000
cases estimated that all the three assays significantly pre-
dict the response to gefitinib in NSCLC patients [29].
Concerning mCRC, Sartore-Bianchi et al [30] sug-
gested that EGFR disomic tumors or with low polysomy
have a reduced likelihood of response to panitumumab
and Moroni et al [10] proposed that the response to
anti-EGFR treatment with cetuximab is strictly related
to EGFR copy number. More recently, it has been
reported that k-ras mutations represent the strongest
predictor for cetuximab failure in EGFR-positive/FISH-
negative cases [12,13]. In contrast, Campanella et al [31]
showed that in mCRC patients treated with chemother-
apy plus cetuximab, increased EGFR GCN was signifi-
cantly associated with a better clinical outcome,
independent of k-ras status.
The lack of correlation between GCN and EGFR over-
expression both in NSCLC and mCRC confirms current
opinion that EGFR IHC positivity does not allow to
accurately select patients eligible for anti-EGFR treat-
ment [24].
In conclusion, our findings indicate that CISH is a
valid method to detect EGFR GCN, also on cell blocks
of lung FNAC and could be used as an alternative to
gene mutation analysis both in NSCLC and in mCRC.
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